New Clinical Development Model of Kadcyla approved for the treatment of early mammary cancer
The United States FDA approved the extended indication of its antibody coupling drug Kadcyla (ado-trastuzumab emtansine) as a postoperative adjunctive therapy for early mammary cancer patients with positive HER2 and still residualRead More…